Lupus & antiphospholipid syndrome
A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients
Authors' conclusion
While limited by a small sample size, this descriptive study showed that GLP1-RAs did not trigger flares above expected background rates and were associated with significantly decreased BMI.
Study context
- Population
- SLE patients in the NYU Lupus Cohort who had used a GLP1-RA (median age 50; 94% female)18 analysed
- Participants
- 24 patients
- Outcome
- SLE flares and new SLE criteria
- Follow-up
- 6-10 months
Methodological detailsdescriptive, single cohort (NYU Lupus Cohort)
- Descriptive
- Single cohort (NYU Lupus Cohort)
Main finding
As reported in the abstract
6-10 months
Mild-to-moderate flare at 6-10 months
1
Patients accumulating new SLE criteria during follow-up
0
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Initially denied insurance coverage for a GLP1-RA | GLP1-RA 50% |
Median BMI reduction vs baseline · 1-4 months
- Median BMI reduced (P = 0.002)
- 3%
Median BMI reduction vs baseline · 6-10 months
- Median BMI reduced (P = 0.001)
- 13%
Safety
| Outcome | Values |
|---|---|
| SLE flare (mild-to-moderate) · 6-10 months | GLP1-RA 1 events |
SLE flare (mild-to-moderate) · 6-10 months
- No patients accumulated new SLE criteria during follow-up
Original publication
A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients. Rheumatology (Oxford). Published 10 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →